Last reviewed · How we verify
[14C ]APG-2575 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
[14C ]APG-2575 ([14C ]APG-2575) — Ascentage Pharma Group Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| [14C ]APG-2575 TARGET | [14C ]APG-2575 | Ascentage Pharma Group Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- [14C ]APG-2575 CI watch — RSS
- [14C ]APG-2575 CI watch — Atom
- [14C ]APG-2575 CI watch — JSON
- [14C ]APG-2575 alone — RSS
Cite this brief
Drug Landscape (2026). [14C ]APG-2575 — Competitive Intelligence Brief. https://druglandscape.com/ci/14c-apg-2575. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab